Skip to main content

Triptorelin Dosage

Medically reviewed by Last updated on Jun 22, 2022.

Applies to the following strengths: 11.25 mg/3 months; 3.75 mg/month; 22.5 mg/6 months; 22.5 mg

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Prostate Cancer

3.75 mg IM every 4 weeks
11.25 mg IM every 12 weeks
22.5 mg IM every 24 weeks


  • Administered as a single IM injection in either buttock; the injection site should be alternated periodically.
  • Due to different release characteristics, the dosage strengths are not additive and must be selected based upon the desired dosing schedule.

Use: For the palliative treatment of advanced prostate cancer

Usual Pediatric Dose for Precocious Puberty

2 years and older:
22.5 mg IM every 24 weeks

Duration of therapy: Therapy should be discontinued at the onset of puberty at the discretion of the physician.


  • This drug should only be administered by a healthcare provider.
  • Monitor response to this drug with LH levels after a GnRH or GnRH agonist stimulation test, basal LH, or serum concentration of sex steroid levels beginning 1 to 2 months following initiation of therapy, during therapy as necessary to confirm maintenance of efficacy, and with each subsequent dose.
  • Measure height (for calculation of growth rate) every 3 to 6 months and monitor bone age periodically.
  • Noncompliance with drug regimen or inadequate dosing may result in inadequate control of the pubertal process with gonadotropins and/or sex steroids increasing above prepubertal levels.
  • If the dose of this drug is not adequate switching to an alternative GnRH agonist for the treatment of CPP with the ability for dose adjustment may be necessary.

Use: For the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP)

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.


CONTRAINDICATIONS (NOTE: Check individual product package inserts for brand name specific information):

  • Hypersensitivity to the active component or any of the ingredients or other GnRH agonists or GnRH
  • Pregnancy

Safety and efficacy have not been established in patients younger than 2 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

  • NOTE: Different products have different indications and dosing. Consult the manufacturer package insert before using product.
  • Must be administered under the supervision of a physician.
  • Alternate injection site periodically.

Storage requirements:
  • Store at room temperature, do not freeze

Reconstitution/preparation techniques:
  • Reconstitute in sterile water only; do not use any other diluent.
  • Administer immediately after reconstitution.
  • The manufacturer product information should be consulted.

Patient advice:
  • Patients are likely to have an increase in testosterone after the first dose, which may worsen their symptoms during the first weeks of treatment.
  • The increased testosterone and symptoms should decline after 3 to 4 weeks.
  • Advise patients that there is an increased risk of developing diabetes, myocardial infarction, sudden cardiac death, and stroke.
  • Advise patients that allergic reactions may occur, and serious reactions require immediate treatment.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.